Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Dennis Ruff"'
Autor:
Kenan Gu, Dennis Ruff, Cassandra Key, Marissa Thompson, Shoshanna Jiang, Taylor Sandison, Shawn Flanagan
Publikováno v:
Clinical and Translational Science, Vol 15, Iss 7, Pp 1592-1598 (2022)
Abstract Rezafungin is a novel echinocandin being developed for the treatment and prevention of invasive fungal infections. The objectives of this randomized, double‐blind study in healthy adults were to determine the safety, tolerability, and phar
Externí odkaz:
https://doaj.org/article/f578c9867a544470bdf7b5fc9bf8704d
Autor:
David G. Soergel, Kimberly A. Ramos, Ian E. James, Michael J. Fossler, Dennis Ruff, Franck Skobieranda
Publikováno v:
Clinical Pharmacology in Drug Development. 11:51-62
TRV734, an oral G-protein biased ligand at the μ-opioid receptor has demonstrated differentiated pharmacology in preclinical studies compared to unbiased ligands. First-time-in-human data suggested that TRV734 was safe and well tolerated and caused
Autor:
Kimberly A. Ramos, Ian E. James, Michael J. Fossler, Dennis Ruff, David G. Soergel, Franck Skobieranda
Publikováno v:
Clinical pharmacology in drug developmentReferences. 9(2)
TRV734 is an orally bioavailable G-protein-biased ligand at the μ-opioid receptor. In nonclinical studies it was potently analgesic while causing less gastrointestinal dysfunction than morphine, suggesting unique benefits in acute pain management. A
Autor:
Michael Hall, Albert T. Profy, Jennifer G. Chickering, Marina Mihova, James Wakefield, G. Todd Milne, Mark G. Currie, John P. Hanrahan, Dennis Ruff, Phebe J. Wilson, Daniel P. Zimmer
Publikováno v:
Diabetes. 67
Background: Impaired nitric oxide (NO) signaling through soluble guanylate cyclase (sGC) has been associated with microvascular complications of diabetes. Praliciguat (IW-1973), an sGC stimulator that enhances NO signaling, reduced fasting plasma glu
Autor:
Albert T. Profy, G. Todd Milne, Marina Mihova, Michael Hall, Dennis Ruff, James Wakefield, Phebe J. Wilson, Mark G. Currie, Jennifer G. Chickering, John P. Hanrahan
Publikováno v:
Clinical pharmacology in drug development. 8(5)
Nitric oxide (NO)-soluble guanylate cyclase (sGC)-cyclic guanosine monophosphate (cGMP) signaling is central to the regulation of several physiological processes, including blood flow and inflammation. Deficient NO signaling is implicated in multiple
Autor:
John Hanrahan, James Wakefield, Phebe Wilson, Marina Mihova, Jennifer Chickering, Dennis Ruff, Michael Hall, Todd Milne, Mark Currie, Albert Profy
Publikováno v:
Hypertension. 70
Background: Soluble guanylate cyclase (sGC), an enzyme that catalyzes the formation of cyclic guanosine monophosphate (cGMP) in response to nitric oxide (NO) binding, is a key mediator of local blood flow, inflammation, and fibrosis. IW-1973 is an or
Publikováno v:
The Journal of Clinical Pharmacology. 54:234-239
This open-label, multi-dose, single-center, sequential, inpatient study evaluated the effects of a two herb combination drug (T89, Danshen plus Sanqi) on the steady-state pharmacodynamics (PD) and pharmacokinetics (PK) of warfarin in 24 healthy volun
Publikováno v:
Annals of the New York Academy of Sciences. 1194:223-229
Synthetic thymosin beta 4 (Tbeta4) may have a potential use in promoting myocardial cell survival during acute myocardial infarction. Four cohorts, with 10 healthy subjects each, were given a single intravenous dose of placebo or synthetic Tbeta4. Co
Publikováno v:
Journal of clinical pharmacology. 54(2)
This open-label, multi-dose, single-center, sequential, inpatient study evaluated the effects of a two herb combination drug (T89, Danshen plus Sanqi) on the steady-state pharmacodynamics (PD) and pharmacokinetics (PK) of warfarin in 24 healthy volun
Autor:
Joel Freiman, Kenny Frazier, Anne Turnage, Brian Zambrowicz, David R. Powell, Phillip Banks, Arthur T. Sands, Ike Ogbaa, Dennis Ruff, Kristi A. Boehm
Publikováno v:
Clinical therapeutics. 35(8)
Background LX4211 is a first-in-class dual inhibitor of sodium-dependent glucose cotransporters 1 and 2 (SGLT1 and SGLT2). SGLT1 is the primary transporter for glucose absorption from the gastrointestinal tract, and SGLT2 is the primary transporter f